THROMBO inCode® Reproductive Health is a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages. The identification of patients at high risk of recurrent miscarriage due to their thrombophilic profile allows thromboprophylaxis to be established to prevent recurrence and increase the likelihood of achieving a full-term pregnancy.
In addition, THROMBO inCode® Reproductive Health analyses the patient’s risk of venous thromboembolism, especially during pregnancy. This period is more prone to the development of thrombosis due to the procoagulant physiological mechanisms that are activated during the antepartum and puerperium phases. Thanks to the recommendations in the outcome report, preventive measures can be established for patients at high risk.
Genes/variants analysed and technology
Using our evidence base, we evaluate the implication of hereditary thrombophilia on the risk of repeated miscarriages as well as the risk of venous thromboembolism.
- Patients who have suffered recurrent pregnancy losses; in other words, at least two spontaneous miscarriages before the 22nd week of pregnancy, not necessarily consecutive.
THROMBO inCode® Reproductive Health is the only scientifically based diagnostic test that enables the study of the involvement of hereditary thrombophilia on the risk of recurrent pregnancy losses.
It has proven to have a greater diagnostic capacity, with a statistically significant difference in comparison with the Factor V Leiden and Prothrombin variants. With THROMBO inCode® Reproductive Health, a thrombophilic causality can be established in a significant proportion of patients with recurrent pregnancy losses.
Numerous scientific articles published in prestigious national and international journals have been written about THROMBO inCode®:
- Soria JM, et al. Multilocus Genetic Risk Scores for Venous Thromboembolism Risk Assessment. J Am Heart Assoc. 2014;3(5):e001060
- Páramo JA et al. Prediction of recurrent pregnancy loss by a new thrombophilia based genetic risk score. IJSBAR 2018;42(4):61-73
- Diaz-Nuñez M et al. Recurrent miscarriage and implantation failure of unknown cause studied by a panel of thrombophilia conditions: Increased frequency of FXIII Val34Leu polymorphism. J Reprod Infertil 2019;20(2):76-82
- Fernández Arias M et al. Genetic risk assessment of thrombophilia in patients with adverse obstetric outcomes. PLOS One 2019. doi:/10.1371/journal.pone.0211114
- McInnes G. Predicting venous thromboembolism risk from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges. Human Mutation. 2019;40:1314–1320
- Salas E. et al. Predictive Ability of a Clinical-Genetic Risk Score for Venous THROMBOembolism in Northern and Southern European Populations. TH Open 2021;5:e303–e311.